Group 2D: Metastatic Breast Cancer; HER2+; Patient Decision-Making; Brain Metastases; Quality of Life

Poster #P5-05-18: Characterizing Patient Experience and Decision Making Associated with Considering Stopping or Pausing HER2-targeted Treatment for MBC Population Using a Questionnaire

Poster #P2-07-08: MRI screening for brain metastases versus SYMptom- directed brain imaging for Patients with Triple neg or HER2+ Metastatic breast cancer: updated primary outcome analysis and preliminary quality of life data from a randomized phase II pilot study